Neurology 1001 - Neurology Alert - Jan 01, 2006

Target Audience:

This activity is intended for the neurologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Physician Editor
Fred Plum, MD
University Professor;
Department of Neurology;
Cornell University Medical College

Associate Editor
John J. Caronna, MD
Vice-Chairman
Department of Neurology
Cornell University Medical Center;
Professor of Clinical Neurology
New York Hospital

Peer Reviewer
M. Flint Beal, MD
Professor and Chairman;
Department of Neurology;
Cornell University Medical College
New York, NY

Assistant Editors
Matthew Fink, MD
Vice Chairman
Professor of Clinical Neurology
Weill Medical College
Chief of Division
Stroke and Critical Care Neurology
New York Presbyterian Hospital

Micheal Rubin, MD
Professor of Clinical Neurology
New York Presbyterian Hospital
Cornell Campus

Claire Henchcliffe, MD, DPhil
Assistant Professor
Department of Neurology
Weill Medical College
Cornell University

Brian R. Apatoff, MD, PhD
Associate Professor of Neurology
New York Presbyterian Hospital
Cornell Campus

Authors
Charles P. Pollak, MD
Professor
Clinical Neurology
Weill College of Medicine

Dara G. Jamieson, MD
Associate Professor
Clinical Neurology
Weill Medical College
Cornell University

Subjects:

  • REM Behavior Disorder: Another Kind of Sleepwalking
  • PFO and Cryptogenic Stroke—What Shall We Do?
  • Not Every Stroke Patient Needs a TEE
  • Lamotrigine for Migraine with Aura
  • Spinal Surgery and ALS
  • Does Modafinil Improve Daytime Somnolence in Parkinson's Disease?
  • Cannabis-Based Medicine for MS Pain
  • Fabry Disease: An Underappreciated Cause of Cryptogenic Ischemic Stroke in Young Adults

Objectives:

  • Present current scientific data regarding diagnosis and treatment of neurologic disease, including stroke, Alzheimer?s disease, transient ischemic attack, and coma
  • Discuss the pathogenesis and treatment of pain
  • Present "basic science? lessons in brain function
  • Discuss information regarding new drugs for commonly diagnosed diseases and new uses for traditional drugs
  • Discuss nonclinical issues of importance to neurologists, such as the right to die and the physician?s legal obligation to patients with terminal illness

Financial Disclosure:

Neurology Alert’s physician editor, Fred Plum, MD and associate editor John J. Caronna, MD report no consultant, stockholder, speaker’s bureau, research, or other relationships related to this field of study. The Peer Reviewer, M. Flint Beal, MD and assistant editor Matthew Fink, MD report no consultant, stockholder, speaker’s bureau, research, or other financial relationship with any company having ties or related to this field of study. Author Charles P. Pollak, MD is a stockholder for Merck, and is on the speaker's bureau for Merck. Assistant editor Micheal Rubin, MD is on the speaker’s bureau for Athena Diagnostics, and does research for Pfizer and Merck. Assistant editor Claire Henchcliffe, MD, DPhil is on the speaker’s bureau for GlaxoSmithKline, Teva/Eisai, and Boehringer Ingelheim. Assistant editor Brian R. Apatoff, MD, PhD is on the speaker’s bureau for Biogen and Teva. Author Dara G. Jamieson, MD is a consultant for Boehringer Ingelheim and Merck, and is on the speaker’s bureau for Boehringer Ingelheim, Merck, Ortho-McNeil, and Pfizer.

Copyright 2006 AHC Media. All rights reserved.